TY - JOUR
TI - Bioassay for determining voriconazole serum levels in patients receiving combination therapy with echinocandins
AU - Siopi, M.
AU - Neroutsos, E.
AU - Zisaki, K.
AU - Gamaletsou, M.
AU - Pirounaki, M.
AU - Tsirigotis, P.
AU - Sipsas, N.
AU - Dokoumetzidis, A.
AU - Goussetis, E.
AU - Zerva, L.
AU - Valsami, G.
AU - Meletiadis, J.
JO - Antimicrobial Agents and Chemotherapy
PY - 2016
VL - 60
TODO - 1
SP - 632-636
PB - American Society for Microbiology
SN - 0066-4804, 1098-6596
TODO - 10.1128/AAC.01688-15
TODO - anidulafungin;  caspofungin;  micafungin;  voriconazole;  antifungal agent;  echinocandin;  voriconazole, agar diffusion;  Article;  bioassay;  blood sampling;  broth dilution;  Candida parapsilosis;  clinical article;  colony forming unit;  comparative study;  controlled study;  drug blood level;  drug determination;  fungus isolation;  high performance liquid chromatography;  human;  in vitro study;  inhibition zone;  monotherapy;  nonhuman;  priority journal;  quality control;  bacterial count;  blood;  Candida;  candidiasis;  combination drug therapy;  drug effects;  growth, development and aging;  microbiology;  regression analysis;  reproducibility;  sensitivity and specificity, Antifungal Agents;  Biological Assay;  Candida;  Candidiasis;  Chromatography, High Pressure Liquid;  Colony Count, Microbial;  Drug Therapy, Combination;  Echinocandins;  Humans;  Quality Control;  Regression Analysis;  Reproducibility of Results;  Sensitivity and Specificity;  Voriconazole
TODO - Voriconazole levels were determined with high-performance liquid chromatography (HPLC) and a microbiological agar diffusion assay using a Candida parapsilosis isolate in 103 serum samples from an HPLC-tested external quality control program (n = 39), 21 patients receiving voriconazole monotherapy (n = 39), and 7 patients receiving combination therapy (n = 25). The results of the bioassay were correlated with the results obtained from the external quality control program samples and with the HPLC results in sera from patients on voriconazole monotherapy and on combination therapy with an echinocandin (Spearman's rank correlation coefficient [rs], > 0.93; mean ± standard error of the mean [SEM] % difference, <12% ± 3.8%). Copyright © 2015, American Society for Microbiology. All Rights Reserved.
ER -